P. 1
Swine Flu Project

Swine Flu Project

|Views: 1,434|Likes:
Published by Archit Patel
This project about the swine flu vaccine .,its recommendation and its growinf factors
This project about the swine flu vaccine .,its recommendation and its growinf factors

More info:

Published by: Archit Patel on Aug 19, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

12/15/2012

pdf

text

original

Pneumococcal disease is caused by a bacterium called Streptococcus pneumonia. There are

more than 90 different types of pneumococcal bacteria; however, only a few types account

for most of the serious diseases. Many people carry S. pneumonia in their throat or nose

without getting sick.

If the bacteria overcome body's natural defenses, then they can cause various diseases. The

most serious of these is meningitis, an inflammation of the tissue surrounding the brain and

spinal cord. Pneumococcal meningitis is fatal in up to 26 percent of cases. Among people

who recover, it can cause permanent health effects, including brain damage and hearing loss.

Other diseases caused by S. pneumonia include bacteremia (blood poisoning), pneumonia

(lung infection), and otitis media (middle ear infections).

Pneumococcal disease is treated with antibiotics, such as penicillin and cephalosporins. In

recent years, certain strains of S. pneumonia have emerged that are resistant to one or more

commonly used antibiotics. This makes prevention of pneumococcal disease through

vaccination even more important.

Market Size of Pneumococcal Vaccines & Future Forecast

At present one product manufactured by Wyeth as the brand name Prevnar is available in the

market. In 2007 Prevnar sales surged 24 percent to US$ 2.4 Billion, making it the first

vaccine to exceed US$ 2 Billion in annual sales. It is estimated that over the next 10 years (by

2018) global immunization funding could be as much as US$ 8 Billion for new vaccines.

The major drivers for the growth of Pneumococcal vaccine is to come from 30 of the 72

GAVI countries expressed interest in introducing pneumococcal conjugate vaccine between

2008 and 2010. These countries are Benin, Burundi, the Republic of Congo, Rep. of Cote

d'Ivoire, Djibouti, the Democratic Republic of Congo, Ethiopia, Ghana, Guyana, Honduras,

Indonesia.

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->